...
首页> 外文期刊>Scientific reports. >Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase
【24h】

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

机译:将标准化的全基因组序列分析与全球结核分枝杆菌抗生素抗性知识库整合

获取原文

摘要

Drug-resistant tuberculosis poses a persistent public health threat. The ReSeqTB platform is a collaborative, curated knowledgebase, designed to standardize and aggregate global Mycobacterium tuberculosis complex (MTBC) variant data from whole genome sequencing (WGS) with phenotypic drug susceptibility testing (DST) and clinical data. We developed a unified analysis variant pipeline (UVP) ( ) to identify variants and assign lineage from MTBC sequence data. Stringent thresholds and quality control measures were incorporated in this open source tool. The pipeline was validated using a well-characterized dataset of 90 diverse MTBC isolates with conventional DST and DNA Sanger sequencing data. The UVP exhibited 98.9% agreement with the variants identified using Sanger sequencing and was 100% concordant with conventional methods of assigning lineage. We analyzed 4636 publicly available MTBC isolates in the ReSeqTB platform representing all seven major MTBC lineages. The variants detected have an above 94% accuracy of predicting drug based on the accompanying DST results in the platform. The aggregation of variants over time in the platform will establish confidence-graded mutations statistically associated with phenotypic drug resistance. These tools serve as critical reference standards for future molecular diagnostic assay developers, researchers, public health agencies and clinicians working towards the control of drug-resistant tuberculosis.
机译:耐药结核病对公共健康构成持续威胁。 ReSeqTB平台是一个合作的,经过整理的知识库,旨在标准化和汇总来自全基因组测序(WGS)的全球结核分枝杆菌复合体(MTBC)变异数据以及表型药物敏感性测试(DST)和临床数据。我们开发了统一的分析变体管线(UVP)(),以从MTBC序列数据中识别变体并分配血统。严格的阈值和质量控制措施已纳入此开源工具中。该管道使用了特征鲜明的90个不同MTBC分离株的数据集进行了验证,并具有常规DST和DNA Sanger测序数据。 UVP与使用Sanger测序鉴定的变体表现出98.9%的一致性,并且与传统的谱系分配方法100%一致。我们在ReSeqTB平台中分析了代表所有七个主要MTBC谱系的4636个公开可用的MTBC分离株。基于平台中随附的DST结果,检测到的变体预测药物的准确性高于94%。随着时间的推移,平台中变体的聚集将建立与表型药物抗性统计相关的置信度分级突变。这些工具可作为未来分子诊断测定开发人员,研究人员,公共卫生机构和临床医生致力于控制耐药性结核病的重要参考标准。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号